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recorded. Each IBD pt with cancer (IBD-K) was matched with 2
IBD pts with no cancer (IBD-C) for:IBD type (Crohn’s Disase, CD vs
Ulcerative Colitis, UC), gender, age (±5 yrs). Statistical analysis: data
expressed as median (range). Wilcoxon, Chi-squared, Fisher’s exact
tests, multivariate logistic analysis were used.
Results: Incident cancer occurred in 236 IBD pts (IBD-K): 129
CD (CD-K), 107 UC (UC-K). The frequency of incident cancer was
higher in CD vs UC (55% vs 45%; p=0.01). Incident cancers (n=236)
included; digestive system (n=80; 34%), skin (n=32; 14%: 16 NMSC,
16 melanoma), urinary tract (n=25; 11%), lung (n=18; 8%), breast
(10%; n=20), genital tract (6%; n=15), thyroid (n=8; 3%), lymphoma
(n=10; 4%), others (n=24; 10%). Lymphoma (n=10) and small bowel
cancers (n=8) occurred only in CD. Comparable cancer frequency in
UC vs CD: digestive system (37% vs 31%; p=0.48); skin. (13% vs 15%;
p=0.19); urinary tracts (14% vs 9%; p=0.27), Colorectal cancer (CRC)
frequency was higher in UC vs CD (32% vs 17%; p=0.02). Risk factors
for any cancer considered:age (<40 vs ≥40 yrs), IBD duration
(<10 vs ≥10 yrs), smoking (Y/N), ISS-anti-TNFs (Y/N), IBD-related
surgery, UC extent, CD pattern (B3 vs B1, B2 vs B1), perianal CD.
Significant risk factor for any cancer were UC-related surgery in UC
(OR [95% CI]): 5.78 [2.38–15.6I]) and perforating pattern in CD: 1.72
[0.92–3.25I. A higher proportion of pts with vs without cancer was
observed penetrating CD (27% [35/129] vs 16% [41/258]; p=0.02)
and in extensive UC (50% [53/107] vs 35% [75/213]; p=0.02). Second
(n=11) or third incident cancers (n=2) occurred in 11 IBD pts.
Conclusions: In a prospective, multicenter, nested-case control
study, CD phenotype, penetrating CD and UC-related surgery were
identified as significant risk factors for incident cancer. Small bowel
cancers and lymphoma occurred only in CD. A high frequency of
second and third incident cancer was observed, thus supporting a
higher cancer risk in subgroups of patients.
OC.12.4
PRIMARY SCLEROSING CHOLANGITIS ASSOCIATEDWITH
INFLAMMATORY BOWEL DISEASE: ANALYSIS OF INTESTINAL
OUTCOME AFTER LIVER TRANSPLANTATION
D. Ribaldone ∗, F. De Blasio, M. Astegiano, G.M. Saracco, S. Reggiani,
D. Reggio, A. Resegotti, M. Vernero, A. Giachetti, A. Tucci
Ospedale Molinette, Torino, Italy
Background and aim: Primary sclerosing cholangitis (PSC) is a
cholestatic disease frequently associated with inflammatory bowel
disease (IBD), that often leads to orthotopic liver transplantation
(OLT). Management of IBD before and after liver transplant for PSC
can be challenging, as there are no official guidelines.
The aim of this study was to evaluate the differences of progression
of intestinal disease between a group of transplanted and a group
of non-transplanted IBD/PSC patients. Secondary objectives were to
evaluate risk factors, including medical therapy, that could influence
the IBD outcome, as well as the incidence of complications and
mortality rates. Intestinal disease activity pre- and post-OLT was
documented as well.
Material and methods: A retrospective analysis of 53 patients with
a diagnosis of IBD/PSC was performed, with a total mean follow-up
time of 18.4 years. The primary outcome was IBD activity, based on
symptomatology, endoscopic assessment and drug use at the last
follow-up examination, as well as anamnestic positivity criteria to
a therapy non-responder disease (colectomy/intestinal resections,
steroid dependency).
Results: During the follow-up period, 27 patients underwent liver
transplant (22 UC,4 CD,1 IBDu); of them a total of 17 presented an
unfavourable outcome of IBD, more than double the portion of non-
transplanted patient (63% vs. 31%, P=0.04). Our analysis showed
that poor IBD outcome can be associated with a tacrolimus-based
immunosuppression (RR=2.15) more frequently than with other
anti-rejection drugs (P=0.02); we found that an active IBD at the
time of transplant (RR=2.05; P=0.05) or an earlier diagnosis of in-
testinal disease can be risk factors for a more aggressive IBD-course.
Other possible risk factors for a poorer outcome are discontinua-
tion of aminosalicylates after transplant, history of extraintestinal
IBD manifestation or PSC complications and feminine gender. An
increased risk of malignancy was detected, with a total of 13
people who developed colon dysplasia during follow-up (25% of
total population), of whom 5 resulted in CRC (9%). Even if most of
the analysed patient did not experience a change of disease activity
after transplant, about 20% of the patients transplanted for PSC
improved, whereas about 30% worsened.
Conclusions: Liver transplant, which is more common in UC pa-
tients due to the higher prevalence of PSC-related liver cirrhosis,
seems to worsen the IBD natural history, although is not clear
what are the mechanisms behind this increase in activity. The
use of tacrolimus-based immunosuppression may be associated
with an unfavourable outcome: in certain patients a shift from
tacrolimus post-transplant maintenance treatment should be con-
sidered. Furthermore, OLT should be performed, when possible, on
patients with non-active IBD at the time of transplant. This study
also emphasises the importance of periodic endoscopic/histologic
surveillance in IBD/PSC patients.
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Background and aim: Vedolizumab is an alpha4beta7 integrin an-
tagonist for the treatment of inflammatory bowel disease (IBD). The
role of drug monitoring, based on the assessment of Vedolizumab
trough levels (VTL) and anti-Vedolizumab antibodies (AVA) has not
been clarified.
Material and methods: Consecutive IBD patients who started ther-
apy with Vedolizumab at our centre were prospectively enrolled.
Each patient underwent 300 mg infusion at weeks 0, 2, 6 and 14;
additional doses at week 10 and then every 4 weeks were given to
non-responders at week 6. Clinical activity was evaluated by Harvey
Bradshaw Index (HBI) and partial Mayo score (pMayo). Patients
were followed up to a median of 36 months. VTL and AVA were
assayed by ELISA (Theradiag) at weeks 6 and 14. Limits of detection
for VTL and AVA were 2 μg/ml and 35 ng/ml, respectively. Clinical
response was defined as at least 30% reduction of activity scores
from baseline and remission was defined as HBI<5 or pMayo <2.
Statistics was performed by Mann Whitney test, Spearman’s rho,
ROC curve analysis.
Results: We included 66 patients (mean age 46.1 y; male 60%)
with Crohn’s disease (CD, n=34) and Ulcerative colitis (UC, n=32).
Median VTL measured at week 6 were significantly higher in clinical
responders as compared to non-responders (41.3 vs 26.9 μg/ml,
p=0.003), and in patients in clinical remission at week 14 (45.6 vs
27.9 μg/ml, p=0.03), at week 22 (46 vs 28.3 μg/ml p=0.012) and at
week 36 (40.2 vs 28.8 μg/ml, p=0.047) compared to non- remitters.
By ROC curve analysis we identified a cut off value for VTL of 40.3
μg/ml for clinical response at week 6 (AUC 0.714, sensitivity 51.6%,
